Problems at plant stall drug
FDA won’t give its OK until Genzyme corrects deficiencies
Genzyme Corp. yesterday said US regulators are delaying approval of Lumizyme, its drug to treat the rare genetic disorder Pompe disease in adults, until the Cambridge biotechnology company solves persistent problems at its cell culture manufacturing plant in Allston. (Full article: 688 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
